Oxford Nanopore Technologies plc National Australian rare disease programme (1968V)
30 Novembre 2023 - 8:00AM
UK Regulatory
TIDMONT
RNS Number : 1968V
Oxford Nanopore Technologies plc
30 November 2023
30 November 2023
Oxford Nanopore Technologies plc
New genomic funding awarded in Australia to boost national rare
disease research programme, using Oxford Nanopore Technologies
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"),
the company delivering a new generation of nanopore-based molecular
sensing technology, today announces that Oxford Nanopore technology
will be used by Dr Ira Deveson in a three-year project at the
Garvan Institute of Medical Research, establishing a national
sequencing programme to address challenging unsolved cases and to
improve the identification of the genetic cause of rare diseases.
The project involves evaluating and optimising nanopore sequencing
for prospective clinical use, as well as determining best practices
for sample preparation, sequencing, and analysis to generate
high-quality, reliable data.
By incorporating long nanopore sequencing reads into rare
genetic disease characterisation, the researchers aim to raise
future diagnostic rates, enabling more patients to receive accurate
recognition and treatments. Identifying new variants and disease
mechanisms may uncover new therapies for these conditions.
Standard gene tests analyse short segments of DNA before
assembling them into a full sequence. This traditional method may
miss large or complex genetic changes that can also cause disease.
By leveraging Oxford Nanopore technology's ability to sequence
any-length fragment of DNA, the researchers will gain a more
comprehensive picture of the genome and will be able to detect
complex genetic variants that traditional sequencing methods often
miss.
Gordon Sanghera, CEO, Oxford Nanopore Technologies,
commented:
"We are delighted for the team and congratulate the researchers
on being awarded this important funding. It is great to see so much
research being dedicated to rare genetic disorders and with
nanopore sequencing data they will get much more comprehensive
insights. What you're missing matters, so with Oxford Nanopore's
ability to sequence any-length fragments of DNA we believe the team
will be able to resolve significant blind spots and we look forward
to hearing about their progress and discoveries."
Dr Ira Deveson, Head of the Genomic Technologies Lab at the
Garvan Institute of Medical Research, commented:
"We believe new generation sequencing technologies will hold the
key to unlocking some of the most challenging unsolved cases of
rare genetic diseases, changing how we characterise and treat these
conditions. Our national programme, involving nanopore sequencing,
will not only increase the future overall diagnostic rate but also
contribute to the discovery of new genetic variants and potential
new treatment approaches for people with rare diseases."
The research team was awarded a grant from the Medical Research
Future Fund Genomics Health Futures Mission. The full Garvan
Institute of Medical Research announcement is available here .
-Ends-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology that is currently used for
real-time, high-performance, accessible, and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries, to
understand the biology of humans, plants, animals, bacteria,
viruses and environments as well as to understand diseases such as
cancer. Oxford Nanopore's technology also has the potential to
provide broad, high impact, rapid insights in a number of areas
including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements.
Phrases such as "potential", "expect", "intend", "believe we can",
"working to", "anticipate", "when validated", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business, and by definition address
matters that are, to different degrees, uncertain and may involve
factors beyond our control.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKKBNABDKKDN
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Oxford Nanopore Technolo... (LSE:ONT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024